Skip to main content
SpringerLink
Log in

Recombinant FVIII appears to be cost effective for severe haemophilia A in the USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was affiliated with Sanofi Genzyme, and funded by Sanofi.

Reference

  • Bullement A, et al. Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States PharmacoEconomics-Open : 20 Jul 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00283-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Recombinant FVIII appears to be cost effective for severe haemophilia A in the USA. PharmacoEcon Outcomes News 883, 26 (2021). https://doi.org/10.1007/s40274-021-7897-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7897-3

Search

Navigation